{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:42:58Z","timestamp":1780375378603,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P500PM_203194"],"award-info":[{"award-number":["P500PM_203194"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.radonc.2025.111088","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T14:15:01Z","timestamp":1754835301000},"page":"111088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG\/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2531-3551","authenticated-orcid":false,"given":"Jonas","family":"Willmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-0793","authenticated-orcid":false,"given":"Joost J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-1869","authenticated-orcid":false,"given":"Orit","family":"Kaidar-Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Abrunhosa-Branquinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-2480","authenticated-orcid":false,"given":"Enrico","family":"Clementel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-6501","authenticated-orcid":false,"given":"Coreen","family":"Corning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Portik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-3147","authenticated-orcid":false,"given":"Jaap C.","family":"Reijneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Dhermain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen","family":"Hurkmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-8441","authenticated-orcid":false,"given":"Angelo Filippo","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Saez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren P.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-5916","authenticated-orcid":false,"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111088_b0005","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0010","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2010.11.039","article-title":"Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704\u2013a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas","volume":"82","author":"Abrams","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111088_b0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jnci\/djt001","article-title":"Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials","volume":"105","author":"Ohri","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2025.111088_b0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2012.08.008","article-title":"QA makes a clinical trial stronger: evidence-based medicine in radiation therapy","volume":"105","author":"Weber","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2011.05.073","article-title":"Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting","volume":"100","author":"Weber","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.radonc.2012.04.015","article-title":"EORTC radiation oncology group quality assurance platform: establishment of a digital central review facility","volume":"103","author":"Fairchild","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0035","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.clon.2017.01.045","article-title":"Evaluating target volume delineation in the era of precision radiotherapy: FRCR, revalidation and beyond","volume":"29","author":"Gwynne","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.radonc.2012.04.002","article-title":"Quality assurance in the EORTC 22033-26033\/CE5 phase III randomized trial for low grade glioma: the digital individual case review","volume":"103","author":"Fairchild","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.radonc.2018.03.013","article-title":"Radiotherapy quality assurance for the RTOG 0834\/EORTC 26053-22054\/NCIC CTG CEC.1\/CATNON intergroup trial \u201cconcurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p\/19q deleted anaplastic glioma\u201d: Individual case review analysis","volume":"127","author":"Abrunhosa-Branquinho","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13014-015-0439-z","article-title":"Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group","volume":"10","author":"Wee","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0055","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2015.07.041","article-title":"CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG oncology and TROG consensus guidelines","volume":"117","author":"Brouwer","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0065","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.radonc.2015.01.016","article-title":"Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist\u2019s guide for delineation in everyday practice","volume":"114","author":"Scoccianti","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0070","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.radonc.2010.06.009","article-title":"Tools for consensus analysis of experts\u2019 contours for radiotherapy structure definitions","volume":"97","author":"Allozi","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2307\/1932409","article-title":"Measures of the amount of ecologic association between species author(s): Lee R. Dice Published by: Ecological Society of America Stable","volume":"26","author":"Dice","year":"1945","journal-title":"Ecology"},{"key":"10.1016\/j.radonc.2025.111088_b0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.radonc.2016.04.028","article-title":"The dosimetric impact of target volume delineation variation for cervical cancer radiotherapy","volume":"120","author":"Eminowicz","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0085","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-019-03152-9","article-title":"NRG brain tumor specialists consensus guidelines for glioblastoma contouring","author":"Kruser","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2025.111088_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0095","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-020-03605-6","article-title":"Glioma consensus contouring recommendations from a MR-linac international consortium research group and evaluation of a CT-MRI and MRI-only workflow","volume":"149","author":"Tseng","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2025.111088_b0100","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0110","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.ejca.2012.06.002","article-title":"Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?","volume":"48","author":"Fairchild","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111088_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110875","article-title":"Clinical impact of radiotherapy quality assurance results in contemporary cancer trials: a systematic review and meta-analysis","volume":"207","author":"Jomy","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0120","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(23)00625-3","article-title":"Radiotherapy trial quality assurance processes: a systematic review","volume":"25","author":"Brooks","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0125","article-title":"Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)","volume":"47","author":"Maier","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0130","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3390\/cancers16112007","article-title":"Radiotherapy plan quality assurance in NRG oncology trials for brain and head\/neck cancers: an AI-enhanced knowledge-based approach","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111088_b0135","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.ijrobp.2020.11.011","article-title":"Using auto-segmentation to reduce contouring and dose inconsistency in clinical trials: the simulated impact on RTOG 0617","volume":"109","author":"Thor","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111088_b0140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fonc.2020.00524","article-title":"CNN-based quality assurance for automatic segmentation of breast cancer in radiotherapy","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.media.2021.102161","article-title":"The predictive value of segmentation metrics on dosimetry in organs at risk of the brain","volume":"73","author":"Poel","year":"2021","journal-title":"Med Image Anal"},{"key":"10.1016\/j.radonc.2025.111088_b0150","article-title":"Transfer learning-based autosegmentation of primary tumor volumes of glioblastomas using preoperative MRI for radiotherapy treatment","volume":"12","author":"Tian","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13014-020-01553-z","article-title":"Fully automated brain resection cavity delineation for radiation target volume definition in glioblastoma patients using deep learning","volume":"15","author":"Ermi\u015f","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2020.10.002","article-title":"The role of computational methods for automating and improving clinical target volume definition","volume":"153","author":"Unkelbach","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2019.06.031","article-title":"Deep learning derived tumor infiltration maps for personalized target definition in Glioblastoma radiotherapy","volume":"138","author":"Peeken","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111088_b0170","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/neuonc\/noad258","article-title":"Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: a new future is on the horizon","volume":"26","author":"Tseng","year":"2024","journal-title":"Neuro Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402504592X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402504592X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:03:42Z","timestamp":1759521822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402504592X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"alternative-id":["S016781402504592X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111088","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG\/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111088"}}